CHINA PHARMA HOLDINGS, INC. Income Statement
CPHI|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
CHINA PHARMA HOLDINGS, INC. reported $4M in revenue and $3M in net loss for FY2025. Revenue has declined at a 18.6% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $7.0M | $7.0M | $8.1M | $10.9M | $10.9M | $12.3M | $13.2M | $15.6M | $20.4M | $22.1M | $32.8M | $54.5M | $81.2M | $74.4M |
| Cost of Revenue | $4.3M | $7.3M | $7.3M | $8.6M | $8.9M | $9.4M | $10.4M | $10.7M | $12.4M | $15.8M | $17.2M | $23.4M | $38.7M | $52.2M | $44.1M |
| Gross Profit | -$131.9K | -$281.1K | -$281.1K | -$493.9K | $2.0M | $1.5M | $2.0M | $2.5M | $3.2M | $1.5M | - | -$480.9K | $14.1M | $29.0M | $30.3M |
| SG&A Expense | $2.5M | $1.5M | $1.5M | $1.9M | $1.8M | $2.3M | $1.9M | $2.0M | $2.3M | $1.9M | $1.7M | $2.4M | $2.9M | $3.7M | $3.0M |
| R&D Expense | $280.9K | $240.1K | $240.1K | $185.9K | $378.0K | $229.6K | $172.4K | $90.5K | $366.0K | $961.9K | - | $1.7M | $438.7K | - | - |
| Operating Income | -$3.2M | -$2.8M | -$2.8M | -$3.5M | -$2.6M | -$20.4M | -$10.4M | -$18.7M | -$8.2M | -$14.3M | -$38.8M | -$18.6M | $5.9M | $22.0M | $24.7M |
| Interest Expense | $27.3K | $30.6K | $30.6K | $434.6K | $294.2K | $321.7K | $451.3K | $539.3K | $849.6K | -$1.2M | $785.8K | -$348.7K | -$308.4K | -$255.2K | -$168.3K |
| Income Tax | - | - | - | - | - | - | -$110.0K | $122.6K | $308.2K | $60.4K | -$77.0K | -$1.1M | -$983.9K | -$3.4M | -$2.7M |
| Net Income | -$3.2M | -$3.1M | -$3.1M | -$4.0M | -$2.9M | -$20.7M | -$10.8M | -$19.3M | -$9.2M | -$15.4M | -$39.6M | -$20.0M | $4.6M | $19.3M | $23.4M |
| EPS (Basic) | -$2.71 | -$0.91 | -$3.78 | -$0.74 | - | - | - | - | - | - | -$0.91 | -$0.46 | $0.11 | $0.44 | $0.54 |
| EPS (Diluted) | -$2.71 | -$0.91 | -$3.78 | -$0.74 | -$0.07 | -$0.48 | -$0.25 | -$0.44 | -$0.21 | -$0.35 | -$0.91 | -$0.46 | $0.11 | $0.44 | $0.54 |
| Shares Outstanding | 3.3M | 10.6M | 1.5M | 4.7M | 45.6M | 43.6M | 43.6M | 43.6M | 43.6M | 43.6M | 43.6M | 43.6M | 43.6M | 43.5M | 42.3M |
| Gross Margin | -3.2% | -4.0% | -4.0% | -6.1% | 18.0% | 13.6% | 16.0% | 18.7% | 20.7% | 7.2% | - | -1.5% | 25.8% | 35.7% | 40.7% |
| Operating Margin | -78.2% | -39.3% | -39.3% | -43.8% | -23.7% | -186.8% | -84.7% | -141.4% | -52.4% | -70.3% | -175.1% | -56.7% | 10.8% | 27.1% | 33.2% |
| Profit Margin | -76.9% | -43.9% | -43.9% | -49.0% | -26.4% | -189.5% | -87.2% | -145.9% | -59.0% | -75.7% | -178.7% | -61.0% | 8.5% | 23.7% | 31.5% |